Phase II Trial of Temsirolimus for Relapsed/Refractory Primary CNS Lymphoma [Clinical Trials]
Conclusion
Single-agent temsirolimus at a weekly dose of 75 mg was found to be active in relapsed/refractory patients with PCNSL; however, responses were usually short lived.
Source: Journal of Clinical Oncology - Category: Cancer & Oncology Authors: Korfel, Schlegel, Herrlinger, Dreyling, Schmidt, von Baumgarten, Pezzutto, Grobosch, Kebir, Thiel, Martus, Kiewe Tags: Brain Tumors Clinical Trials Source Type: research
More News: Anemia | Brain | Brain Cancers | Brain Tumor | Cancer & Oncology | Chemotherapy | Clinical Trials | Lymphoma | Methotrexate | Neurology | Primary CNS Lymphoma | Stem Cell Therapy | Stem Cells | Study | Thrombocytopenia | Toxicology | Transplants